An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
Soria, Francesco (San Giovanni Battista Hospital)
Droller, Michael J. (Mount Sinai School of Medicine (New York, Estats Units d'Amèrica))
Lotan, Yair (University of Texas Southwestern Medical Center. Department of Urology)
Gontero, Paolo (San Giovanni Battista Hospital)
D'Andrea, David (Universitätskliniken der MedUni Wien)
Gust, Kilian M. (Universitätskliniken der MedUni Wien)
Rouprêt, Morgan (Assistance Publique-Hôpitaux de Paris Sorbonne Université. Department of Urology, Hôpital Pitié-Salpétrière)
Babjuk, Marek (Universitätskliniken der MedUni Wien)
Palou, Juan (Institut d'Investigació Biomèdica Sant Pau)
Shariat, Shahrokh (Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria)
Universitat Autònoma de Barcelona

Fecha:	2018
Resumen:	With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers have been identified and tested for bladder cancer (BCa) surveillance. To summarize the current status of urinary biomarkers for the detection of recurrence and/or progression in the follow-up of non-muscle invasive BCa patients, and to assess the value of urinary biomarkers in predicting response to intravesical Bacillus Calmette-Guerin (BCG) therapy. A medline/pubmed© literature search was performed. The performance of commercially available and investigational biomarkers has been reviewed. End points were cancer detection (recurrence), cancer progression, and response to BCG therapy. The performance requirements for biomarkers are variable according to the clinical scenario. The clinical role of urinary biomarkers in the follow-up of non-muscle invasive BCa patients remains undefined. The FDA-approved tests provide unsatisfactory sensitivity and specificity levels and their use is limited. Fluorescence in situ hybridization (FISH) has been shown to be useful in specific scenarios, mostly as a reflex test and in the setting of equivocal urinary cytology. FISH and immunocytology could conceivably be used to assess BCG response. Recently developed biomarkers have shown promising results; upcoming large trials will test their utility in specific clinical scenarios in a manner similar to a phased drug development strategy. Current commercially available urinary biomarker-based tests are not sufficiently validated to be widely used in clinical practice. Several novel biomarkers are currently under investigation. Prospective multicenter analyses will be needed to establish their clinical relevance and value.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Urinary biomarker ; Test ; Follow-up ; Surveillance ; Non-muscle invasive bladder cancer ; Recurrence
Publicado en:	World journal of urology, Vol. 36 (june 2018) , p. 1981-1995, ISSN 1433-8726

DOI: 10.1007/s00345-018-2380-x
PMID: 29931526

15 p, 1.0 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados